RESUMO
Approximately 80 million people globally are affected by glaucoma, with a projected increase to over 110 million by 2040. Substantial issues surrounding patient compliance remain with topical eye drops, and up to 10% of patients become treatment resistant, putting them at risk of permanent vision loss. The major risk factor for glaucoma is elevated intraocular pressure, which is regulated by the balance between the secretion of aqueous humor and the resistance to its flow across the conventional outflow pathway. Here, we show that adeno-associated virus 9 (AAV9)-mediated expression of matrix metalloproteinase-3 (MMP-3) can increase outflow in two murine models of glaucoma and in nonhuman primates. We show that long-term AAV9 transduction of the corneal endothelium in the nonhuman primate is safe and well tolerated. Last, MMP-3 increases outflow in donor human eyes. Collectively, our data suggest that glaucoma can be readily treated with gene therapy-based methods, paving the way for deployment in clinical trials.
Assuntos
Glaucoma , Pressão Intraocular , Humanos , Animais , Camundongos , Metaloproteinase 3 da Matriz/metabolismo , Glaucoma/genética , Glaucoma/terapia , Glaucoma/metabolismo , Humor Aquoso/metabolismo , Terapia GenéticaRESUMO
Retinal ganglion cells (RGCs) are known to be involved in several ocular disorders, including glaucoma and Leber hereditary optic neuropathy (LHON), and hence represent target cells for gene therapies directed towards these diseases. Restricting gene therapeutics to the target cell type in many situations may be preferable compared to ubiquitous transgene expression, stimulating researchers to identify RGC-specific promoters, particularly promoter sequences that may also be appropriate in size to fit readily into recombinant adeno associated viral (AAV) vectors, the vector of choice for many ocular gene therapies. In the current study we analysed EGFP expression driven by various sequences of the putative human NEFH promoter in order to define sequences required for preferential expression in RGCs. EGFP expression profiles from four different potential NEFH promoter constructs were compared in vivo in mice using retinal histology and mRNA expression analysis. Notably, two efficient promoter sequences, one comprising just 199 bp, are presented in the study.
Assuntos
Proteínas de Neurofilamentos/genética , Regiões Promotoras Genéticas/genética , Células Ganglionares da Retina/metabolismo , Animais , Pareamento de Bases , Dependovirus/genética , Expressão Gênica/genética , Regulação da Expressão Gênica/genética , Terapia Genética , Vetores Genéticos , Glaucoma/patologia , Humanos , Camundongos , Camundongos da Linhagem 129 , Proteínas de Neurofilamentos/metabolismo , Atrofia Óptica Hereditária de Leber/patologia , Retina/patologia , Células Ganglionares da Retina/fisiologia , TransgenesRESUMO
AAV9 drives gene expression in a highly selective manner within the corneal endothelium of mice following intracameral inoculation into the anterior chamber of the eye. In principle, this allows genes encoding protein constituents of the secretome (representing up to 20% of the human proteome) to be delivered directly into the aqueous humor. From here the secreted protein moves with the natural flow of the aqueous humor via a pressure gradient and is directed toward the outflow tissues. Such a delivery can be employed to modulate outflow facility and intraocular pressure through interactions at the trabecular meshwork and Schlemm's canal. We provide a protocol for the delivery of AAV to the corneal endothelium, using a CMV-driven eGFP reporter gene as a marker.
Assuntos
Dependovirus/genética , Endotélio Corneano/metabolismo , Expressão Gênica , Técnicas de Transferência de Genes , Vetores Genéticos/genética , Transgenes , Animais , Genes Reporter , Vetores Genéticos/administração & dosagem , Humanos , Imuno-Histoquímica , Camundongos , Microscopia de Fluorescência , Transdução GenéticaRESUMO
Significant advances in gene therapy have enabled exploration of therapies for inherited retinal disorders, many of which are in preclinical development or clinical evaluation. Gene therapy for retinal conditions has led the way in this growing field. The loss of retinal ganglion cells (RGCs) is a hallmark of a number of retinal disorders. As the field matures innovations that aid in refining therapies and optimizing efficacy are in demand. Gene therapies under development for RGC-related disorders, when delivered with recombinant adeno associated vectors (AAV), have typically been expressed from ubiquitous promoter sequences. Here we describe how a novel promoter from the murine Nefh gene was selected to drive transgene expression in RGCs. The Nefh promoter, in an AAV2/2 vector, was shown to drive preferential EGFP expression in murine RGCs in vivo following intravitreal injection. In contrast, EGFP expression from a CMV promoter was observed not only in RGCs, but throughout the inner nuclear layer and in amacrine cells located within the ganglion cell layer (GCL). Of note, the Nefh promoter sequence is sufficiently compact to be readily accommodated in AAV vectors, where transgene size represents a significant constraint. Moreover, this promoter should in principle provide a more targeted and potentially safer alternative for RGC-directed gene therapies.
RESUMO
Intraocular pressure (IOP) is maintained as a result of the balance between production of aqueous humour (AH) by the ciliary processes and hydrodynamic resistance to its outflow through the conventional outflow pathway comprising the trabecular meshwork (TM) and Schlemm's canal (SC). Elevated IOP, which can be caused by increased resistance to AH outflow, is a major risk factor for open-angle glaucoma. Matrix metalloproteinases (MMPs) contribute to conventional aqueous outflow homeostasis in their capacity to remodel extracellular matrices, which has a direct impact on aqueous outflow resistance and IOP. We observed decreased MMP-3 activity in human glaucomatous AH compared to age-matched normotensive control AH. Treatment with glaucomatous AH resulted in significantly increased transendothelial resistance of SC endothelial and TM cell monolayers and reduced monolayer permeability when compared to control AH, or supplemented treatment with exogenous MMP-3.Intracameral inoculation of AAV-2/9 containing a CMV-driven MMP-3 gene (AAV-MMP-3) into wild type mice resulted in efficient transduction of corneal endothelium and an increase in aqueous concentration and activity of MMP-3. Most importantly, AAV-mediated expression of MMP-3 increased outflow facility and decreased IOP, and controlled expression using an inducible promoter activated by topical administration of doxycycline achieved the same effect. Ultrastructural analysis of MMP-3 treated matrices by transmission electron microscopy revealed remodelling and degradation of core extracellular matrix components. These results indicate that periodic induction, via use of an eye drop, of AAV-mediated secretion of MMP-3 into AH could have therapeutic potential for those cases of glaucoma that are sub-optimally responsive to conventional pressure-reducing medications.
Assuntos
Dependovirus/genética , Glaucoma/terapia , Pressão Intraocular/genética , Metaloproteinase 3 da Matriz/genética , Animais , Humor Aquoso/metabolismo , Modelos Animais de Doenças , Endotélio Corneano/metabolismo , Endotélio Corneano/patologia , Glaucoma/genética , Glaucoma/patologia , Humanos , Metaloproteinase 3 da Matriz/uso terapêutico , Camundongos , Soluções Oftálmicas/uso terapêuticoRESUMO
PURPOSE: Age-related macular degeneration is the most common form of central retinal blindness in the elderly. Of the two end stages of disease, neovascular AMD-although the minority form-is the most severe. Current therapies are highly successful at controlling progression of neovascular lesions; however, a significant number of patients remain refractory to treatment and the development of alternative and additive therapies to anti-VEGFs is essential. METHODS: In order to address the translational potential of interleukin (IL)-18 for use in neovascular AMD, we initiated a nonhuman primate tolerability and efficacy study for the use of intravitreally (IVT) administered clinical grade human IL-18 (SB-485232). Cynomolgus monkeys were injected IVT with increasing doses of human IL-18 (two each at 1000, 3000, and 10,000 ng per eye). In tandem, 21 monkeys were administered nine laser burns in each eye prior to receiving IL-18 as an IVT injection at a range of doses. Fundus fluorescein angiography (FFA) was performed on days 8, 15, and 22 post injection and the development of neovascular lesions was assessed. RESULTS: We show intravitreal, mature, recombinant human IL-18 is safe and can reduce choroidal neovascular lesion development in cynomolgus monkeys. CONCLUSIONS: Based on our data comparing human IL-18 to current anti-VEGF-based therapy, clinical deployment of IL-18 for neovascular AMD has the potential to lead to a new adjuvant immunotherapy-based treatment for this severe form of central blindness.
Assuntos
Células Endoteliais/patologia , Imunoterapia/métodos , Interleucina-18/administração & dosagem , Degeneração Macular/tratamento farmacológico , Neovascularização Retiniana/tratamento farmacológico , Animais , Western Blotting , Modelos Animais de Doenças , Eletrorretinografia , Células Endoteliais/metabolismo , Feminino , Angiofluoresceinografia , Fundo de Olho , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , Injeções Intravítreas , Macaca fascicularis , Degeneração Macular/diagnóstico , Degeneração Macular/etiologia , Camundongos , Camundongos Mutantes , Reação em Cadeia da Polimerase , Primatas , RNA/genética , Retina/metabolismo , Retina/patologia , Retina/fisiopatologia , Neovascularização Retiniana/complicações , Neovascularização Retiniana/diagnóstico , Resultado do Tratamento , Fator A de Crescimento do Endotélio Vascular/biossíntese , Fator A de Crescimento do Endotélio Vascular/genéticaRESUMO
As gene therapies for various forms of retinal degeneration progress toward human clinical trial, it will be essential to have a repertoire of safe and efficient vectors for gene delivery to the target cells. Recombinant adeno-associated virus (AAV) serotype 2/2 has been shown to be well tolerated in the human retina and has provided efficacy in human patients for some inherited retinal degenerations. In this study, the AAV2/8 and AAV2/rh10 serotypes have been compared as a means of gene delivery to mammalian photoreceptor cells using a photoreceptor specific promoter for transgene expression. Both AAV2/8 and AAV2/rh10 provided rescue of the retinal degeneration present in the rhodopsin knockout mouse, with similar levels of benefit as evaluated by molecular, histological, and functional readouts. Transgene expression levels were significantly higher (fivefold) 1 week postsubretinal injection when employing AAV2/8 for rhodopsin gene delivery compared to AAV2/rh10, and were indistinguishable by 6 weeks postadministration of vector. This study reports the use of the AAV2/rh10 serotype to provide rescue in a degenerating retina and provides a comparative evaluation of AAV2/rh10 with respect to AAV2/8, a serotype regarded as providing efficient delivery to photoreceptors.
RESUMO
Age-related macular degeneration (AMD) is the most common form of central retinal blindness globally. Distinct processes of the innate immune system, specifically activation of the NLRP3 inflammasome, have been shown to play a central role in the development of both "dry" and neovascular ("wet") forms of the disease. We show that the inflammatory cytokine interleukin-18 (IL-18) can regulate choroidal neovascularization formation in mice. We observed that exogenous administration of mature recombinant IL-18 has no effect on retinal pigment epithelial (RPE) cell viability, but that overexpression of pro-IL-18 or pro-IL-1ß alone can cause RPE cell swelling and subsequent atrophy, a process that can be inhibited by the promotion of autophagy. A direct comparison of local and systemic administration of mature recombinant IL-18 with current anti-VEGF (vascular endothelial growth factor)-based therapeutic strategies shows that IL-18 treatment works effectively alone and more effectively in combination with anti-VEGF therapy and represents a novel therapeutic strategy for the treatment of wet AMD.
Assuntos
Neovascularização de Coroide/tratamento farmacológico , Neovascularização de Coroide/prevenção & controle , Interleucina-18/uso terapêutico , Degeneração Macular/tratamento farmacológico , Animais , Autofagia/efeitos dos fármacos , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Neovascularização de Coroide/complicações , Neovascularização de Coroide/patologia , Hematopoese/efeitos dos fármacos , Humanos , Interleucina-18/farmacologia , Interleucina-1beta/farmacologia , Interleucina-1beta/uso terapêutico , Injeções Intravítreas , Lasers , Degeneração Macular/complicações , Degeneração Macular/patologia , Camundongos , Modelos Biológicos , Permeabilidade/efeitos dos fármacos , Epitélio Pigmentado da Retina/efeitos dos fármacos , Epitélio Pigmentado da Retina/patologia , Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores , Fator A de Crescimento do Endotélio Vascular/metabolismoRESUMO
Leber hereditary optic neuropathy (LHON) is a mitochondrially inherited form of visual dysfunction caused by mutations in several genes encoding subunits of the mitochondrial respiratory NADH-ubiquinone oxidoreductase complex (complex I). Development of gene therapies for LHON has been impeded by genetic heterogeneity and the need to deliver therapies to the mitochondria of retinal ganglion cells (RGCs), the cells primarily affected in LHON. The therapy under development entails intraocular injection of a nuclear yeast gene NADH-quinone oxidoreductase (NDI1) that encodes a single subunit complex I equivalent and as such is mutation independent. NDI1 is imported into mitochondria due to an endogenous mitochondrial localisation signal. Intravitreal injection represents a clinically relevant route of delivery to RGCs not previously used for NDI1. In this study, recombinant adenoassociated virus (AAV) serotype 2 expressing NDI1 (AAV-NDI1) was shown to protect RGCs in a rotenone-induced murine model of LHON. AAV-NDI1 significantly reduced RGC death by 1.5-fold and optic nerve atrophy by 1.4-fold. This led to a significant preservation of retinal function as assessed by manganese enhanced magnetic resonance imaging and optokinetic responses. Intraocular injection of AAV-NDI1 overcomes many barriers previously associated with developing therapies for LHON and holds great therapeutic promise for a mitochondrial disorder for which there are no effective therapies.
Assuntos
Dependovirus/genética , Complexo I de Transporte de Elétrons/genética , Vetores Genéticos/administração & dosagem , Atrofia Óptica Hereditária de Leber/patologia , Atrofia Óptica Hereditária de Leber/terapia , Animais , Modelos Animais de Doenças , Humanos , Injeções Intravítreas , Camundongos , Proteínas Associadas aos Microtúbulos/genética , Atrofia Óptica/patologia , Atrofia Óptica/terapia , Células Ganglionares da Retina/patologia , Proteínas de Saccharomyces cerevisiae/genéticaRESUMO
The inner blood-retina barrier (iBRB) is essential in restricting the movement of systemic components such as enzymes, anaphylatoxins, or pathogens that could otherwise enter the neural retina and cause extensive damage. The barrier has evolved to confer protection to the delicate microenvironment of the retina, and the tight junctions located between adjacent microvascular endothelial cells can restrict the passage of up to 98% of clinically validated low-molecular-weight therapeutics which could hold significant promise for a range of degenerative retinal conditions. Here, we describe a method for the selective RNAi-mediated targeting of one component of the tight junction, claudin-5. We outline the generation of a doxycycline inducible adeno-associated viral vector for the localized, inducible, and size-selective modulation of the iBRB and describe how this vector can be used in ophthalmology research.
Assuntos
Barreira Hematorretiniana/metabolismo , Claudina-5/genética , Vetores Genéticos/administração & dosagem , Interferência de RNA , RNA Interferente Pequeno/administração & dosagem , Adenoviridae/genética , Adenoviridae/metabolismo , Animais , Sequência de Bases , Doxiciclina/metabolismo , Sistemas de Liberação de Medicamentos , Expressão Gênica , Vetores Genéticos/genética , Vetores Genéticos/metabolismo , Injeções Intraoculares , Camundongos , Dados de Sequência Molecular , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/metabolismo , Junções Íntimas/genéticaRESUMO
Cell transplantation to treat retinal degenerative diseases represents an option for the replacement of lost photoreceptor cells. In vitro expandable cells isolated from the developing mammalian retina have been suggested as a potential source for the generation of high numbers of donor photoreceptors. In this study we used standardized culture conditions based on the presence of the mitogens FGF-2 and EGF to generate high numbers of cells in vitro from the developing mouse retina. These presumptive 'retinal stem cells' ('RSCs') can be propagated as monolayer cultures over multiple passages, express markers of undifferentiated neural cells, and generate neuronal and glial cell types upon withdrawal of mitogens in vitro or following transplantation into the adult mouse retina. The proportion of neuronal differentiation can be significantly increased by stepwise removal of mitogens and inhibition of the notch signaling pathway. However, 'RSCs', by contrast to their primary counterparts in vivo, i.e. retinal progenitor cells, loose the expression of retina-specific progenitor markers like Rax and Chx10 after passaging and fail to differentiate into photoreceptors both in vitro or after intraretinal transplantation. Notably, 'RSCs' can be induced to differentiate into myelinating oligodendrocytes, a cell type not generated by primary retinal progenitor cells. Based on these findings we conclude that 'RSCs' expanded in high concentrations of FGF-2 and EGF loose their retinal identity and acquire features of in vitro expandable neural stem-like cells making them an inappropriate cell source for strategies aimed at replacing photoreceptor cells in the degenerated retina.
Assuntos
Diferenciação Celular , Bainha de Mielina/fisiologia , Células Fotorreceptoras de Vertebrados/citologia , Retina/crescimento & desenvolvimento , Células-Tronco/citologia , Animais , Astrócitos/citologia , Astrócitos/efeitos dos fármacos , Axônios/efeitos dos fármacos , Axônios/metabolismo , Diferenciação Celular/efeitos dos fármacos , Regulação para Baixo/efeitos dos fármacos , Fator de Crescimento Epidérmico/farmacologia , Fator 2 de Crescimento de Fibroblastos/farmacologia , Camundongos , Camundongos Endogâmicos C57BL , Bainha de Mielina/efeitos dos fármacos , Especificidade de Órgãos , Células Fotorreceptoras de Vertebrados/efeitos dos fármacos , Receptores Notch/metabolismo , Transdução de Sinais/efeitos dos fármacos , Transplante de Células-Tronco , Células-Tronco/efeitos dos fármacos , Células-Tronco/metabolismoRESUMO
Recombinant adeno-associated virus (AAV) represents an efficient system for neuronal transduction. However, a potential drawback of AAV is its restricted packaging capacity of approximately 5 kb. To bypass this limitation, a number of dual- and triple-vector strategies divide the transgene(s) between two or three AAVs. The success of these approaches relies directly on efficient cotransduction of the component AAVs. Although proof of concept for these stratagems has been demonstrated, the underlying cotransduction rate has not been analyzed quantitatively. In this study, cotransduction efficiencies in both retina and hippocampus have been investigated, using two reporter AAVs expressing either a green (GFP) or red (DsR) fluorescent protein. Transduction efficiencies were monitored via microscopy, flow cytometry, and quantitative PCR. After viral transduction with 1.5×10(9) viral particles of each of the reporter AAVs, approximately one-third of the retinal cells expressed one or both transgenes at levels detectable by native fluorescence. Notably, the majority of the remaining retinal cells were also transduced and expressed the reporters at lower levels, which were detectable only by immunolabeling. Flow cytometric analysis demonstrated cotransduction rates of up to 55% with the two reporter AAVs in retinal cells. Modifying the ratio of the two coadministered AAVs resulted in altered mRNA expression levels of the two reporter genes in cotransduced cell populations. The study suggests that codelivery of AAV is an efficient means of expanding the therapeutic application of AAV in neurons.
Assuntos
Dependovirus/genética , Técnicas de Transferência de Genes , Hipocampo/metabolismo , Retina/metabolismo , Animais , Citometria de Fluxo , Genes Reporter , Vetores Genéticos , Células HeLa , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Ratos , Ratos Wistar , Transdução GenéticaRESUMO
Traumatic brain injury is the leading cause of death in children and young adults globally. Malignant cerebral oedema has a major role in the pathophysiology that evolves after severe traumatic brain injury. Added to this is the significant morbidity and mortality from cerebral oedema associated with acute stroke, hypoxic ischemic coma, neurological cancers and brain infection. Therapeutic strategies to prevent cerebral oedema are limited and, if brain swelling persists, the risks of permanent brain damage or mortality are greatly exacerbated. Here we show that a temporary and size-selective modulation of the blood-brain barrier allows enhanced movement of water from the brain to the blood and significantly impacts on brain swelling. We also show cognitive improvement in mice with focal cerebral oedema following administration in these animals of short interfering RNA directed against claudin-5. These observations may have profound consequences for early intervention in cases of traumatic brain injury, or indeed any neurological condition where cerebral oedema is the hallmark pathology.
Assuntos
Edema Encefálico/etiologia , Edema Encefálico/terapia , Lesões Encefálicas/complicações , Claudinas/metabolismo , Cognição/fisiologia , Animais , Barreira Hematoencefálica/metabolismo , Edema Encefálico/diagnóstico por imagem , Lesões Encefálicas/diagnóstico por imagem , Criança , Claudina-5 , Claudinas/genética , Humanos , Pressão Intracraniana/fisiologia , Masculino , Camundongos , Interferência de RNA , Tomografia Computadorizada por Raios XRESUMO
The blood-retina barrier (BRB) is composed of both an inner and an outer barrier. The outer BRB refers to the barrier formed at the retinal pigment epithelial (RPE) cell layer and functions, in part, to regulate the movement of solutes and nutrients from the choroid to the sub-retinal space. In contrast, the inner BRB, similar to the blood brain barrier (BBB) is located in the inner retinal microvasculature and comprises the microvascular endothelium which line these vessels. The tight junctions located between these cells mediate highly selective diffusion of molecules from the blood to the retina and the barrier is essential in maintaining retinal homeostasis. In this chapter, we summarize the key differences between the iBRB and oBRB and outline the molecular constituents of the tight junctions associated with the iBRB. We also describe a process for modulation of the iBRB to enhance systemic delivery of therapeutics to the retina, a technology which may pave the way for safer and more effective therapies for retinal diseases.
Assuntos
Barreira Hematorretiniana/metabolismo , Retina/metabolismo , Epitélio Pigmentado da Retina/irrigação sanguínea , Junções Íntimas/metabolismo , Animais , Barreira Hematorretiniana/fisiologia , Permeabilidade Capilar , Claudinas/metabolismo , Dependovirus/genética , Dependovirus/metabolismo , Técnicas de Transferência de Genes , Humanos , Células Madin Darby de Rim Canino , Mamíferos , Ocludina/metabolismo , Fosforilação , Interferência de RNA , Retina/fisiologia , Doenças Retinianas/metabolismo , Doenças Retinianas/patologia , Doenças Retinianas/terapia , Epitélio Pigmentado da Retina/metabolismo , Vasos Retinianos/metabolismo , Junções Íntimas/genética , Proteína da Zônula de Oclusão-1/metabolismoRESUMO
Assessment of tight junction integrity in vitro is fundamental when studying molecular processes that may be implicated in barrier dysfunction. At the blood brain and inner blood retina barrier (BBB and iBRB, respectively) adjacent endothelial cells lining the microvasculature have been shown to have very low rates of fluid phase transcytosis and high electrical resistances, due in part to the expression of tight junction proteins at the apical periphery of these cells. While these high electrical resistances are difficult to achieve in vitro, owing to complex interactions of endothelial cells in vivo with astrocytes and pericytes, it is possible to make an assessment of paracellular permeability when cells are analysed on a number of different fronts. In this regard, we will outline here a method for determining trans-endothelial electrical resistance, tracer molecule diffusion, and tight junction protein localization in primary cultures of bovine retinal microvascular endothelial cells. This system allows for the screening of a wide range of pro- and anti-angiogenic molecules in an in vitro model of the iBRB and can accurately assess the role individual tight junction proteins play in maintaining tight junction integrity in response to various cell stimuli.
Assuntos
Barreira Hematorretiniana/metabolismo , Células Endoteliais/metabolismo , Endotélio Vascular/metabolismo , Potenciometria/métodos , Retina/metabolismo , Junções Íntimas/metabolismo , Animais , Barreira Hematorretiniana/efeitos dos fármacos , Western Blotting , Permeabilidade Capilar/efeitos dos fármacos , Bovinos , Células Cultivadas , Cultura em Câmaras de Difusão , Impedância Elétrica , Eletroforese em Gel de Poliacrilamida , Endostatinas/farmacologia , Células Endoteliais/citologia , Células Endoteliais/efeitos dos fármacos , Endotélio Vascular/citologia , Endotélio Vascular/efeitos dos fármacos , Fluorescência , Imuno-Histoquímica , Proteínas de Membrana/análise , Proteínas de Membrana/biossíntese , Microscopia Confocal , Ocludina , Permeabilidade/efeitos dos fármacos , Cultura Primária de Células , Retina/citologia , Junções Íntimas/efeitos dos fármacos , Fator A de Crescimento do Endotélio Vascular/farmacologiaRESUMO
We describe a procedure for controlled, periodic, reversible modulation of selected regions of the blood-brain barrier (BBB) or the inner-blood-retina barrier (iBRB) based on incorporation into an AAV-2/9 vector of a doxycycline-inducible gene encoding shRNA targeting claudin-5, one of 30 or so proteins constituting the BBB and iBRB. The vector may be introduced stereotaxically into pre-selected regions of the brain or into the retina, rendering these regions permeable to low-molecular weight compounds up to approximately 1 kDa for the period of time during which the inducing agent, doxycycline, is administered in drinking water, but excluding potentially toxic higher molecular weight materials. We report on the use of barrier modulation in tandem with systemic drug therapy to prevent retinal degeneration and to suppress laser-induced choroidal neovascularization (CNV), the latter being the hallmark pathology associated with the exudative, or wet, form of age-related macular degeneration (AMD). These observations constitute the basis of a minimally invasive systemic therapeutic modality for retinal diseases, including retinitis pigmentosa and AMD, where, in early stage disease, the iBRB is intact and impervious to systemically administered drugs.
Assuntos
Barreira Hematorretiniana/efeitos dos fármacos , Sistemas de Liberação de Medicamentos/métodos , Terapia Genética , Degeneração Macular/terapia , Animais , Barreira Hematorretiniana/inervação , Barreira Hematorretiniana/metabolismo , Linhagem Celular , Claudina-5 , Dependovirus/genética , Dependovirus/metabolismo , Modelos Animais de Doenças , Vetores Genéticos/genética , Vetores Genéticos/metabolismo , Humanos , Degeneração Macular/genética , Degeneração Macular/metabolismo , Proteínas de Membrana/genética , Proteínas de Membrana/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Peso Molecular , RNA Interferente Pequeno/genética , RNA Interferente Pequeno/metabolismo , RNA Interferente Pequeno/uso terapêuticoRESUMO
For dominantly inherited disorders development of gene therapies, targeting the primary genetic lesion has been impeded by mutational heterogeneity. An example is rhodopsin-linked autosomal dominant retinitis pigmentosa with over 150 mutations in the rhodopsin gene. Validation of a mutation-independent suppression and replacement gene therapy for this disorder has been undertaken. The therapy provides a means of correcting the genetic defect in a mutation-independent manner thereby circumventing the mutational diversity. Separate adeno-associated virus (AAV) vectors were used to deliver an RNA interference (RNAi)-based rhodopsin suppressor and a codon-modified rhodopsin replacement gene resistant to suppression due to nucleotide alterations at degenerate positions over the RNAi target site. Viruses were subretinally coinjected into P347S mice, a model of dominant rhodopsin-linked retinitis pigmentosa. Benefit in retinal function and structure detected by electroretinography (ERG) and histology, respectively, was observed for at least 5 months. Notably, the photoreceptor cell layer, absent in 5-month-old untreated retinas, contained 3-4 layers of nuclei, whereas photoreceptor ultrastructure, assessed by transmission electron microscopy (TEM) improved significantly. The study provides compelling evidence that codelivered suppression and replacement is beneficial, representing a significant step toward the clinic. Additionally, dual-vector delivery of combined therapeutics represents an exciting approach, which is potentially applicable to other inherited disorders.
Assuntos
Terapia Genética/métodos , Retinose Pigmentar/terapia , Animais , Modelos Animais de Doenças , Eletrorretinografia , Camundongos , Camundongos Transgênicos , Reação em Cadeia da PolimeraseRESUMO
Retinal degeneration (RD) results from photoreceptor apoptosis. Cell transplantation, one potential therapeutic approach, requires expandable stem cells that can form mature photoreceptors when differentiated. Freshly dissociated primary retinal cells from postnatal day 2-6 (PN2-6) mouse retina can give rise, post-transplantation, to photoreceptors in adult recipients. Unfortunately, incorporation rates are low; moreover, photoreceptor potential is lost if the same PN2-6 cells are cultured prior to transplantation. We investigated the identity of the cells forming photoreceptors post-transplantation, using FACS sorted primary postnatal day (PN) 3-5 Rho-eGFP retinal cells. Higher integration rates were achieved for cells that were expressing Rho-eGFP at PN3-5, indicating that post-mitotic photoreceptor precursors already expressing rhodopsin form the majority of integrating rods. We then investigated improvement of cell culture protocols for retinal progenitor cells (RPCs) derived from PN3-5 retinal cells in vitro. We succeeded in improving RPC survival and growth rates 25-fold, by modifying retinal dissociation, replacing N2 supplement with B27 supplement minus retinoic acid (B27-RA) and coating flasks with fibronectin. However, levels of rhodopsin and similar photoreceptor-specific markers still diminished rapidly during growth in vitro, and did not re-appear after in vitro differentiation. Similarly, transplanted RPCs, whether proliferating or differentiated, did not form photoreceptors in vivo. Cultured RPCs upregulate genes such as Sox2 and nestin, markers of more primitive neural stem cells. Use of these cells for RD treatment will require identification of triggers that favour terminal photoreceptor differentiation and survival in vitro prior to transplantation.
Assuntos
Sobrevivência Celular , Células Fotorreceptoras de Vertebrados/patologia , Retina/patologia , Transplante de Células-Tronco , Células-Tronco/patologia , Animais , Animais Recém-Nascidos , Técnicas de Cultura de Células , Diferenciação Celular , Proliferação de Células , Citometria de Fluxo , Técnica Indireta de Fluorescência para Anticorpo , Perfilação da Expressão Gênica , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/metabolismo , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Células Fotorreceptoras de Vertebrados/metabolismo , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , Retina/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Rodopsina/genética , Rodopsina/metabolismoRESUMO
Retinitis pigmentosa refers to a diverse group of hereditary diseases that lead to incurable blindness, affecting two million people worldwide. As a common pathology, rod photoreceptors die early, whereas light-insensitive, morphologically altered cone photoreceptors persist longer. It is unknown if these cones are accessible for therapeutic intervention. Here, we show that expression of archaebacterial halorhodopsin in light-insensitive cones can substitute for the native phototransduction cascade and restore light sensitivity in mouse models of retinitis pigmentosa. Resensitized photoreceptors activate all retinal cone pathways, drive sophisticated retinal circuit functions (including directional selectivity), activate cortical circuits, and mediate visually guided behaviors. Using human ex vivo retinas, we show that halorhodopsin can reactivate light-insensitive human photoreceptors. Finally, we identified blind patients with persisting, light-insensitive cones for potential halorhodopsin-based therapy.
Assuntos
Terapia Genética , Halorrodopsinas/genética , Halorrodopsinas/metabolismo , Células Fotorreceptoras Retinianas Cones/fisiologia , Retinose Pigmentar/terapia , Animais , Dependovirus/genética , Modelos Animais de Doenças , Potenciais Evocados Visuais , Vetores Genéticos , Halobacteriaceae/genética , Humanos , Luz , Camundongos , Camundongos Knockout , Regiões Promotoras Genéticas , Retina/fisiologia , Células Ganglionares da Retina/fisiologia , Retinose Pigmentar/fisiopatologia , Técnicas de Cultura de Tecidos , Transfecção , Visão Ocular , Vias Visuais/fisiologiaRESUMO
IMPORTANCE OF THE FIELD: Efficient systemic delivery of low-molecular-mass therapeutics to neuronal tissue remains a central issue not only to drug development but also to the chronic treatment of a range of neurodegenerative disorders. AREAS COVERED IN THIS REVIEW: This review discusses the potential of using RNA interference to modulate tight junction proteins at the blood-brain barrier and inner blood-retina barrier. Both systemic delivery of short-interfering RNA and viral-mediated delivery of short hairpin RNA are discussed, highlighting the therapeutic area relevant to each. WHAT THE READER WILL GAIN: Readers will gain an insight into the potential of size-selective and reversible modulation of neuronal barriers and the types of low-molecular-mass molecule that could be used in the treatment of various neurodegenerative or neuromalignant disorders. TAKE HOME MESSAGE: The purpose of this review is to describe a new therapeutic strategy for systemic delivery of low-molecular-mass therapeutics to neuronal tissues.